Clinical Protocols

Oncology Division

Oncology Clinical Trials

 

 

Hematology Division

Click on the title of a protocol to view its description in ClinicalTrials.gov.
 

Disease Protocol (Sponsor) Status PI/Contact Comments
Thrombosis ATTRACT (NIH) Ongoing; closed to enrollment PI: Suresh Vedantham
Contact: Morey Blinder
mblinder@dom.wustl.edu
New DVT
Sickle Cell Disease A Phase II Trial of Regadenoson in Sickle Cell Anemia (Dana-Farber Cancer Institute) Open to enrollment PI: Elaine Majerus
Contact: Lisa Garrett
lgarrett@dom.wustl.edu
HbSS and S Beta Null
Sickle Cell Disease Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD) (NKT Therapeutics) Ongoing; closed to enrollment PI: Elaine Majerus
Contact: Lisa Garrett
lgarrett@dom.wustl.edu
Hb SS and S Beta Null
PNH Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry (Alexion) Open to enrollment PI: Elaine Majerus
Contact: Vanetta Worthy
vworthy@dom.wustl.edu
PNH Registry
Atypical HUS Atypcial Hemolytic-Uremic Syndrome (aHUS) Registry (Alexion) Open to enrollment PI: Elaine Majerus
Contact: Vanetta Worthy
vworthy@dom.wustl.edu
Atypical HUS
Hemophilia/Bleeding American Thrombosis and Hemostasis Network Data Collection Open PI: Elaine Majerus
Contact: Bill Berger
bberger@wustl.edu
Hemophilia A and B My Life Our Future: Genotyping of Patients with Hemophilia A or B and Tissue Repository Open PI: Elaine Majerus
Contact: Bill Berger
bberger@wustl.edu
Bleeding and clotting disorders CDC Community Counts: Surveillance Project for Patients with Bleeding and Blood Clotting Disorders Open PI: Elaine Majerus
Contact: Bill Berger
bberger@wustl.edu
Banking Laboratory Studies Blood Acquistion for Investigation of Thrombotic Disorders (NIH) Open PI: Elaine Majerus
Contact: Lisa Garrett
lgarrett@dom.wustl.edu
Thrombosis Banking
Myelofibrosis Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis (Gilead) Ongoing; closed to enrollment PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
No prior JAKi therapy
Myelofibrosis Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF (Gilead) Closed to enrollment PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
Prior JAKi therapy allowed
Polycythemia Vera Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL) (Incyte) Ongoing; closed to enrollment PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
 
CNL/aCML Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia (Incyte/OHSU) Open to enrollment PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
 
Myelofibrosis Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia (Gilead) Enrolling by invitation only PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
 
Myelofibrosis Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants with Imtermediate-2 or High-Risk Myelofibrosis Previously Treated with Janus Kinase (JAK) Inhibitor Open to enrollment PI: Stephen Oh
Contact: Nicole Gaudin
ngaudin@dom.wustl.edu
314-747-7960
Myelofibrosis relapsed after or refractory to JAK inhibitor treatment
Myelofibrosis Momelotinib in Transfusion-Dependent Adults with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thromocythemia Myelofibrosis (Post-PV/ET MF) Open to enrollment PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
 
TTP/microangiopathy Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura Open to enrollment PI: Evan Sadler
Contact: Vanetta Worthy
worthyv@wustl.edu
314-362-9998
Low dose Rituximab for TTP